A phase I/II study of adoptive immunotherapy using donor liver graft-derived NK cell-enriched immune cells to prevent severe infection after liver transplantation.
Bloodstream infections (BSIs) are significant postoperative complications associated with high mortality rates after liver transplantation (LT). Natural killer (NK) cells, which are key components of the innate immune system, have demonstrated potential to combat both infections and cancer. The use...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0313102 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849417325740032000 |
|---|---|
| author | Masahiro Ohira Yuki Imaoka Koki Sato Koki Imaoka Tomoaki Bekki Takuya Yano Ryosuke Nakano Hiroshi Sakai Shintaro Kuroda Hiroyuki Tahara Kentaro Ide Tsuyoshi Kobayashi Yuka Tanaka Junko Tanaka Hideki Ohdan |
| author_facet | Masahiro Ohira Yuki Imaoka Koki Sato Koki Imaoka Tomoaki Bekki Takuya Yano Ryosuke Nakano Hiroshi Sakai Shintaro Kuroda Hiroyuki Tahara Kentaro Ide Tsuyoshi Kobayashi Yuka Tanaka Junko Tanaka Hideki Ohdan |
| author_sort | Masahiro Ohira |
| collection | DOAJ |
| description | Bloodstream infections (BSIs) are significant postoperative complications associated with high mortality rates after liver transplantation (LT). Natural killer (NK) cells, which are key components of the innate immune system, have demonstrated potential to combat both infections and cancer. The use of activated NK cells to mitigate post-LT infections, particularly BSIs, has attracted considerable interest. We conducted a single-arm Phase I/II clinical trial to evaluate the safety and efficacy of transfusing donor liver-derived NK cells into LT recipients. Patients were administered a single infusion of these NK cells three days post-LT. The primary endpoint was BSI incidence. This study was terminated in 19 patients because of the high incidence of BSIs. Of the 19 patients receiving immunotherapy, six (31.5%) developed BSIs within one month of LT. No adverse events were directly related to NK cell infusion. Acute rejection was noted in seven patients (36.8%). After infusion, NK cell activity in the recipient's peripheral blood remained stable. In conclusion, this clinical trial did not reach the primary endpoint. This could be attributed to a significant percentage of patients presenting with high immunological risk. Nonetheless, the infusion procedure demonstrated a favorable safety profile without serious adverse events. |
| format | Article |
| id | doaj-art-3243c0fd071c4a90ae5ae84edc4d34b1 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-3243c0fd071c4a90ae5ae84edc4d34b12025-08-20T03:32:53ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01201e031310210.1371/journal.pone.0313102A phase I/II study of adoptive immunotherapy using donor liver graft-derived NK cell-enriched immune cells to prevent severe infection after liver transplantation.Masahiro OhiraYuki ImaokaKoki SatoKoki ImaokaTomoaki BekkiTakuya YanoRyosuke NakanoHiroshi SakaiShintaro KurodaHiroyuki TaharaKentaro IdeTsuyoshi KobayashiYuka TanakaJunko TanakaHideki OhdanBloodstream infections (BSIs) are significant postoperative complications associated with high mortality rates after liver transplantation (LT). Natural killer (NK) cells, which are key components of the innate immune system, have demonstrated potential to combat both infections and cancer. The use of activated NK cells to mitigate post-LT infections, particularly BSIs, has attracted considerable interest. We conducted a single-arm Phase I/II clinical trial to evaluate the safety and efficacy of transfusing donor liver-derived NK cells into LT recipients. Patients were administered a single infusion of these NK cells three days post-LT. The primary endpoint was BSI incidence. This study was terminated in 19 patients because of the high incidence of BSIs. Of the 19 patients receiving immunotherapy, six (31.5%) developed BSIs within one month of LT. No adverse events were directly related to NK cell infusion. Acute rejection was noted in seven patients (36.8%). After infusion, NK cell activity in the recipient's peripheral blood remained stable. In conclusion, this clinical trial did not reach the primary endpoint. This could be attributed to a significant percentage of patients presenting with high immunological risk. Nonetheless, the infusion procedure demonstrated a favorable safety profile without serious adverse events.https://doi.org/10.1371/journal.pone.0313102 |
| spellingShingle | Masahiro Ohira Yuki Imaoka Koki Sato Koki Imaoka Tomoaki Bekki Takuya Yano Ryosuke Nakano Hiroshi Sakai Shintaro Kuroda Hiroyuki Tahara Kentaro Ide Tsuyoshi Kobayashi Yuka Tanaka Junko Tanaka Hideki Ohdan A phase I/II study of adoptive immunotherapy using donor liver graft-derived NK cell-enriched immune cells to prevent severe infection after liver transplantation. PLoS ONE |
| title | A phase I/II study of adoptive immunotherapy using donor liver graft-derived NK cell-enriched immune cells to prevent severe infection after liver transplantation. |
| title_full | A phase I/II study of adoptive immunotherapy using donor liver graft-derived NK cell-enriched immune cells to prevent severe infection after liver transplantation. |
| title_fullStr | A phase I/II study of adoptive immunotherapy using donor liver graft-derived NK cell-enriched immune cells to prevent severe infection after liver transplantation. |
| title_full_unstemmed | A phase I/II study of adoptive immunotherapy using donor liver graft-derived NK cell-enriched immune cells to prevent severe infection after liver transplantation. |
| title_short | A phase I/II study of adoptive immunotherapy using donor liver graft-derived NK cell-enriched immune cells to prevent severe infection after liver transplantation. |
| title_sort | phase i ii study of adoptive immunotherapy using donor liver graft derived nk cell enriched immune cells to prevent severe infection after liver transplantation |
| url | https://doi.org/10.1371/journal.pone.0313102 |
| work_keys_str_mv | AT masahiroohira aphaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT yukiimaoka aphaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT kokisato aphaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT kokiimaoka aphaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT tomoakibekki aphaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT takuyayano aphaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT ryosukenakano aphaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT hiroshisakai aphaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT shintarokuroda aphaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT hiroyukitahara aphaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT kentaroide aphaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT tsuyoshikobayashi aphaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT yukatanaka aphaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT junkotanaka aphaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT hidekiohdan aphaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT masahiroohira phaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT yukiimaoka phaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT kokisato phaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT kokiimaoka phaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT tomoakibekki phaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT takuyayano phaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT ryosukenakano phaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT hiroshisakai phaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT shintarokuroda phaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT hiroyukitahara phaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT kentaroide phaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT tsuyoshikobayashi phaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT yukatanaka phaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT junkotanaka phaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation AT hidekiohdan phaseiiistudyofadoptiveimmunotherapyusingdonorlivergraftderivednkcellenrichedimmunecellstopreventsevereinfectionafterlivertransplantation |